-
Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder
06 Jul 2025 16:41 GMT
… disorders.
Roche’s Actemra already enables steroid tapering … arm. On secondary trial goals measuring cumulative … diseases,” Novartis Chief Medical Officer Shreeram Aradhye said … treatment of plaque psoriasis. Since then, the drug has landed additional FDA …
-
Novartis’ Cosentyx shows no benefit in Phase III GCA trial
04 Jul 2025 16:06 GMT
… countries.
Novartis’ chief medical officer Dr Shreeram Aradhye, … treatment. Patients may also be treated with Actemra (tocilizumab … and Drug Administration (FDA) in January 2015 for the treatment … industry insights.
Clinical Trials Arena Excellence Awards - …
-
Novartis drug flunks phase 3 test in giant cell arteritis
03 Jul 2025 12:53 GMT
… warrant additional testing of the drug in GCA.
While disappointing for … are already approved by the FDA for GCA.
In 2017, … ;s anti-IL-6 antibody Actemra (tocilizumab) was approved for adults … treatment for the disorder based on results of the SELECT-GCA trial …
-
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
02 Jul 2025 19:31 GMT
… escalation portion of the trial investigated linvoseltamab’s safety … Actemra; Genentech) to treat CRS.1,4,5
The FDA … Standard of Care Treatments. National Library of Medicine. ClinicalTrials.gov … Multiple Myeloma. Applied Clinical Trials. Published June 17, 2024 …
-
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
01 Jul 2025 02:55 GMT
… Janssen Biotech, Inc)
Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals Corporation)
… access to tocilizumab (Actemra; Genentech). Patients are … treatments while continuing to prioritize safety.”
References
FDA … ;/www.fda.gov/vaccines-blood-biologics…
-
FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies
30 Jun 2025 21:34 GMT
… delivery of potentially curative treatments to patients and … to ensure drug safety in certain medications with serious … site access to tocilizumab (Actemra; Genentech), which is … treatments while continuing to prioritize safety.”1
REFERENCES
1. FDA. FDA …
-
FDA Approves Updated Labels on CAR T-Cell Therapies, Eliminating REMS
27 Jun 2025 16:32 GMT
… typically mandated for drugs or therapies with … FDA has now determined that the extensive experience gained by the medical … supportive care, tocilizumab (Actemra), and corticosteroids.
Ultimately, … administrative burden on treatment centers, thereby facilitating …
-
Tarlatamab and the ES-SCLC Treatment Landscape: Managing AEs and Educating Patients
19 Jun 2025 23:08 GMT
… research, and professor of medicine; Michelle Sittig, RN, OCN … chemotherapy.
Prior to those trials, patients received 6 cycles … randomized trial where after the standard induction treatment with … using something like tocilizumab [Actemra], but if something is …
-
Uveitis Treatment Market Size to Reach USD 4.69 Billion by 2032, Driven by Advancements in Biologics and Rising Prevalence of Autoimmune Disorders – SNS Insider
19 Jun 2025 13:51 GMT
… Pharmaceuticals – Rocklatan (netarsudil/latanoprost)
Amgen – Enbrel (etanercept)
Roche – Actemra … other medications are … key pharmaceutical and biotechnology companies … Trial Trends and Drug Development Pipeline
6. Competitive Landscape
7. Uveitis Treatment …
-
Rheumatoid Arthritis Global and Regional Market Analysis Report 2025-2035: Revolutionary Biologic Therapies Transform Treatment, Biosimilars Drive Competition and Accessibility - ResearchAndMarkets.com
13 Jun 2025 15:01 GMT
… pharmaceutical companies leading the way in the development of innovative treatments … pipeline of next-generation drugs targeting novel pathways … 6 inhibitors (such as Actemra), and JAK inhibitors (such … by limited access to medications in developing countries …